Myomo (MYO) investor relations material

Executive summary

• Q2 2025 revenue grew 28% year-over-year to $9.7M, driven by higher unit sales and a 14% increase in average selling price, with 56% of revenue from Medicare Part B and 15% from Germany.

• Net loss widened to $4.6M for Q2 2025, reflecting increased investments in R&D, marketing, and reimbursement capacity.

• Gross margin declined to 62.7% from 70.8% due to higher material, demo unit, and overhead costs.

• Direct billing channel contributed 77% of Q2 revenue, up from 55% in Q2 2024.

• Management shifted advertising from digital to TV and reduced workforce by 8% to improve lead quality and control costs.

Financial highlights

• Q2 2025 revenue was $9.7M (up 28% YoY); year-to-date revenue $19.5M (up 73% YoY).

• Gross margin for Q2 2025 was 62.7%, down from 70.8% a year ago.

• Operating expenses rose 65% to $10.6M, mainly from increased advertising, payroll, and R&D.

• Operating loss was $4.6M (vs. $1.1M prior year); net loss was $4.6M or $0.11/share.

• Adjusted EBITDA for Q2 2025 was negative $4.0M (vs. negative $1.2M prior year).

Outlook and guidance

• Q3 2025 revenue expected between $9.5M and $10M; full-year 2025 revenue guidance revised to $40–42M, representing 23–29% growth over 2024.

• Management expects continued net losses and negative cash flows for all of 2025.

• Actions to reduce cash expenditures by at least $2M over the next 12 months, including an 8% workforce reduction.

• Guidance assumes current Medicare Advantage authorization and pipeline conversion rates persist, with moderate improvement in Medicare Part B patient flow.

• Existing cash and investments expected to fund operations for at least the next 12 months.